Drug
Cebranopadol clinical trials
Also written GRT6005 and TRN-228.
- studies test it
- 18
- open now
- 2
- in phase 3
- 5
- first study started
- 2009
Keep track of what changes. Save the cebranopadol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2022 | 2 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
- Pain
- 1
Who runs them
Industry 18 · Other 0
Tris Pharma, Inc. (16) · Adneuris Therapeutics, Inc. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cebranopadol is read from its arms, and is right about nine times in ten.
Testing it · 18
- An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical OriginRecruitingPhase 3Adneuris Therapeutics, Inc.NCT07845071Written as Cebranopadol 400 ug
- A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic PainRecruitingPhase 2Adneuris Therapeutics, Inc.NCT07874620Written as Cebranopadol
- A Study of Cebranopadol for the Treatment of Acute Pain After BunionectomyCompletedPhase 3Tris Pharma, Inc.NCT06423703Written as Cebranopadol
- A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyCompletedPhase 3Tris Pharma, Inc.NCT06545097Written as Cebranopadol 400 ug
- A Study to Assess the Abuse Potential of Intranasal CebranopadolCompletedPhase 1Tris Pharma, Inc.NCT06453265Written as Cebranopadol- 600 ug
- Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.CompletedPhase 1Tris Pharma, Inc.NCT05491785Written as Cebranopadol 600 µg
- Assessment of Abuse Potential of Cebranopadol in HumansCompletedPhase 1Tris Pharma, Inc.NCT05256108Written as Cebranopadol 600 µg
- A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of CebranopadolCompletedPhase 1Tris Pharma, Inc.NCT03882762Written as Cebranopadol 200 μg tablet
- Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesCompletedPhase 2Tris Pharma, Inc.NCT01939366Written as Cebranopadol 100 µg
- Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy SubjectsCompletedPhase 1Tris Pharma, Inc.NCT03958123Written as 100 μg cebranopadol
- Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee PainCompletedPhase 2Tris Pharma, Inc.NCT01709214Written as Cebranopadol (GRT6005) Low-Dose Range
- Assessment of GRT6005 in Painful Osteoarthritis of the KneeCompletedPhase 2Tris Pharma, Inc.NCT01357837Written as GRT6005
- CORAL XT - Open-label Extension Trial of the CORAL TrialCompletedPhase 3Tris Pharma, Inc.NCT02031432Written as Cebranopadol
- Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.CompletedPhase 2Tris Pharma, Inc.NCT01725087Written as Low Dose GRT6005
- Bunionectomy Trial With GRT6005CompletedPhase 2Tris Pharma, Inc.NCT00872885Written as GRT6005
- Painful Diabetic Polyneuropathy Trial With a New Centrally Acting AnalgesicCompletedPhase 2Tris Pharma, Inc.NCT00878293Written as GRT6005
- Safety and Efficacy of GRT6005 in Pain Due to Diabetic PolyneuropathyCompletedPhase 2Tris Pharma, Inc.NCT01347671Written as GRT6005
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to CancerTerminatedPhase 3Tris Pharma, Inc.NCT01964378Written as Cebranopadol
Codes
What other systems call cebranopadol · ClinicalTrials.gg INT000022
- UNII (FDA) 7GDW9S3GN3CEBRANOPADOLOne source FDA
- NCI Thesaurus C112002CebranopadolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7GDW9S3GN3 | CEBRANOPADOL | One source FDA |
| NCI Thesaurus | C112002 | Cebranopadol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.